CardioVax Announces Name Change to Abcentra

Reflects Strategic Commitment to a Novel Drug Target for Inflammatory Disease LOS ANGELES, Jan. 30, 2019 -- (Healthcare Sales & Marketing Network) -- CardioVax, a privately held, clinical-stage biopharmaceutical company developing novel antibody therap... Biopharmaceuticals Abcentra, CardioVax, low-density lipoprotein
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news